Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay

Personalis, Inc.

Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.
Personalis issued two warrants to Tempus to purchase up to 4,609,400 shares each at $1.50 and $2.50 per share.
Tempus will market Personalis' NeXT Personal Dx assay for breast cancer, lung cancer, and immuno-oncology monitoring.
The agreement has a five-year term with exclusivity until December 31, 2027, and includes milestones for up to $12M in fees.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Personalis, Inc. entered into Commercialization and Reference Laboratory Agreement with Tempus Labs, Inc. valued at up to $12,000,000 in the aggregate (effective 2023-11-25).

Action: entry
Agreement: collaboration
Counterparty: Tempus Labs, Inc.
Value: up to $12,000,000 in the aggregate
Effective: 2023-11-25

Exact text from the filing

On November 25, 2023 (the “Effective Date”), Personalis, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Commercialization and Reference Laboratory Agreement (the “Tempus Agreement”)

View on SEC.gov

Browse all material agreements →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-066458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.